Get the Stockscreener App
208.45
0.04%
0.09
Pre-market:
208.45
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $208.45, with a volume of 488.00K.
It is up +0.04% in the last 24 hours and up +10.16% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$208.36
Open:
$208.14
24h Volume:
488.00K
Relative Volume:
0.49
Market Cap:
$22.98B
Revenue:
$10.52B
Net Income/Loss:
$999.00M
P/E Ratio:
24.93
EPS:
8.3628
Net Cash Flow:
$1.22B
1W Performance:
+0.31%
1M Performance:
+10.16%
6M Performance:
+15.73%
1Y Performance:
+19.11%
1-Day Range:
$207.11
$209.76
1-Week Range:
$203.89
$213.50
52-Week Range:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
208.45 | 22.97B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics (NYSE: DGX) EVP sells shares and disposes stock for taxes - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP sells 526 shares in plan - Stock Titan
Quest Diagnostics (NYSE: DGX) CEO discloses 10,000-share stock sale - Stock Titan
Quest Diagnostics (DGX) SVP sells and withholds shares under plan - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP covers tax obligations with share sale - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports tax-withholding stock disposition on Form 4 - Stock Titan
Quest Diagnostics Remains a Dominant Competitor in Independent Labs - Morningstar
Catherine Doherty reports 27,598 DGX share dispositions in Form 144 (NYSE: DGX) - Stock Titan
DGX insider sale notice (DGX) — 526 vested shares; prior 1,111 sold - Stock Titan
Insider sale notice for DGX (DGX): Plewman lists proposed share disposals - Stock Titan
Victory Capital Management Inc. Sells 465,252 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
DGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quest Diagnostics launches AI tool to analyze lab results By Investing.com - Investing.com Canada
DGX (NYSE: DGX) Form 144 shows proposed sale of 10,000 shares - Stock Titan
Quest Diagnostics Rolls Out Gemini-Powered AI Tool to Explain Lab Results - marketscreener.com
New Quest AI chat uses 5 years of lab data to spot potential health risks - Stock Titan
Quest Diagnostics Inc. (NYSE:DGX) Stands Out as a Sustainable Dividend Stock - ChartMill
Quest Diagnostics Incorporated $DGX Position Lowered by IVY Lane Capital Management LLC - MarketBeat
Bahl & Gaynor Inc. Decreases Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
APG Asset Management N.V. Cuts Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Bought by American Century Companies Inc. - MarketBeat
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Quest Diagnostics Incorporated $DGX Shares Sold by Vestmark Advisory Solutions Inc. - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Quest Diagnostics (NYSE:DGX) Sets New 1-Year HighWhat's Next? - MarketBeat
Quest Diagnostics stock reaches all-time high at 213.21 USD By Investing.com - Investing.com Canada
Quest Diagnostics appoints Beauvalot to SVP, chief strategy and M&A officer - ROI-NJ
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement - TipRanks
In Insight Molecular Diagnostics Inc. Enters into A Specimen Collection Agreement with Quest Diagnostics Incorporated - marketscreener.com
Quest Diagnostics Announces Appointment of Benjamin Beauvalot as Senior Vice President, Chief Strategy and M&A Officer - marketscreener.com
After nearly 80 deals, Quest Diagnostics names new M&A chief - Stock Titan
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Insight Molecular Diagnostics Inc. has reached a service agreement with Quest Diagnostics. - Bitget
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference - Finviz
Quest Diagnostics CFO to outline strategy, market trends at Leerink 2026 event - Stock Titan
Citigroup Inc. Acquires 25,666 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth - Yahoo Finance
Quest Diagnostics (NYSE:DGX) EVP Sells $293,521.39 in Stock - Defense World
Quest Diagnostics (NYSE:DGX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Compass Wealth Management LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - Defense World
ANTIPODES PARTNERS Ltd Has $11.76 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) SVP Sells $196,227.14 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 1,111 Shares of Stock - MarketBeat
Quest Diagnostics (NYSE: DGX) CEO awarded options and RSUs, shares withheld for taxes - Stock Titan
Quest Diagnostics (DGX) EVP logs stock sale, option and RSU awards - Stock Titan
Quest Diagnostics (DGX) SVP logs option, RSU grants and tax share disposals - Stock Titan
Dividend plan boosts Quest Diagnostics (NYSE: DGX) director holdings - Stock Titan
Quest Diagnostics (DGX) director acquires 67 shares through dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP gets options, RSUs and tax withholdings - Stock Titan
A diagnostics company moved out. Its former landlord claims it left a mess. - The Business Journals
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):